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Reactive oxygen speciesAutophagy, literally translated means self-eating, is a primary degradative pathway and plays an important role
in the regulation of cellular homeostasis through elimination of aggregated proteins, damaged organelles, and in-
tracellular pathogens. Autophagy has been classiﬁed into microautophagy, macroautophagy, and chaperone-
mediated autophagy, depending on the choice of the pathway bywhich the cellularmaterial is delivered to lyso-
somes. Dysregulation of autophagy may contribute to the development of cardiorenal metabolic syndrome
(CRS), including insulin resistance, obesity, hypertension, maladaptive immune modulation, and associated
cardiac and renal disease. Clarifying the pathways and mechanisms of autophagy under normal conditions is
essential to understanding its dysregulation in the development of CRS. Here, we highlight a recent surge in au-
tophagy research, such as the cellular quality control through the disposal and recycling of cellular components,
and summarize our contemporary understanding ofmolecularmechanisms of autophagy in diverse organ or tis-
sues involved in the pathogenesis of CRS. This article is part of a Special Issue entitled: Autophagy and protein
quality control in cardiometabolic diseases.
© 2014 Published by Elsevier B.V.1. Introduction
The term “autophagy”was coined by Christian de Duve based on his
discovery of lysosomes,whichwon him theNobel Prize in Physiology or
Medicine in 1974 [1]. Autophagy is a cellular degradation pathway that
maintains cellular homeostasis through the degradation and recycles
cytoplasm components constitutively in response to environmental
conditions, such as starvation, endoplasmic reticulum (ER) stress and
increased reactive oxygen species (ROS) [2]. There are three types of
cell death: apoptosis, necrosis and autophagy. Apoptotic cell death,
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ers).of cytoplasm and chromatin, DNA fragmentation, and cell fragmenta-
tion into apoptotic bodies, followed by removal and degradation of the
dying cells by phagocytosis [3]. Autophagy cell death type 2 pro-
grammed cell death is characterized by the accumulation of autophagic
vesicles such as autophagosomes and autophagolysosomes. This pro-
cess is often observed when massive cell elimination is demanded or
when phagocytes do not have easy access to the dying cells [4]. One fea-
ture that distinguishes apoptosis from autophagic cell death is the
source of the lysosomal enzymes used for degradation of dying cells.
Apoptotic cells use phagocytic cell lysosomes for this process, whereas
cells with autophagic morphology use the dying cells' endogenous lyso-
somal machinery in autophagy [5] (Fig. 1).
Autophagy has been classiﬁed into three different types, including
microautophagy, macroautophagy, and chaperone-mediated autopha-
gy. Autophagy removes damaged intracellular macromolecules and or-
ganelles and plays a protective role for cell survival [6]. Therefore,
autophagy not only plays a principal role in the supply of nutrients for
cell survival but also plays a constitutive role in cellular homeostasis
by acting as a cytoplasmic quality control mechanism to eliminate old
or unfolded proteins and damaged organelles [7]. One possible mecha-
nism for autophagy cell protection is elimination of damagedmitochon-
dria, which leads to mitochondrial outer membrane permeabilization
and consequent apoptosis. Autophagy involves sequestration of pro-
teins and cell organelles in autophagosomes, which direct them to lyso-
somes. The formation of autophagosomes is dependent on the induction
of several genes, including microtubule-associated protein 1 light chain
Fig. 1. Proposed dysregulation of autophagy in the development of CRS. Autophagy is an extremely complex and tightly regulated cellular process in various human physiological and
pathological processes. Many factors such as nutrient status, ER stress, inﬂammation, aswell as ROS regulate the autophagy throughmTOR, AMPK, and Sirts signaling pathways and even-
tually cause dysfunction of heart, vascular, adipose, skeletal muscle, and pancreatic β-cells in CRS. These pathophysiological changes furthermore bring out the risk factors in the dysreg-
ulation of autophagy in a potentially vicious cycle manner.
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agy plays a critical role in the clearance of degenerated proteins and se-
nescent organelles aswell as in themaintenance of cellular homeostasis
during energy starvation or stress, dysregulated autophagy has been im-
plicated in the pathogenesis of cardiorenal metabolic syndrome (CRS),
which consists of a constellation of cardiac, renal and metabolic disor-
ders including insulin resistance, obesity, metabolic dyslipidemia, mal-
adaptive immune responses and evidence of early cardiac and renal
disease [9,10]. Here, we summarize the current understanding of the
molecularmechanismof autophagy and the role of autophagy in diverse
organs or tissues involved in CRS.
2. Molecular mechanisms and regulation of signaling pathways
in autophagy
Autophagy is an extremely complex and tightly regulated cellular
phenomenon that involves various physiological and pathological
processes. Autophagy incorporates signaling through the mammalian
target of rapamycin (mTOR), 5′ adenosine monophosphate-activated
protein kinase (AMPK), and silent information regulator (Sirt) path-
ways. These steps are induction, nucleation, elongation of phagophores,
sequestration of cytosolic components through autophagosome forma-
tion, transport to the lysosome, degradation, and utilization of degrada-
tion products [11].
2.1. The process of autophagy
The autophagy process begins with the generation of cup-shaped
structures called phagophores or isolation membranes mediated
by the serine/threonine protein kinase UNC51-like kinase 1 (ULK1)signaling. The two ULK1 sites most dephosphorylated in response to
starvation are S638 and S758, which are considered to be mTOR sites,
whereas, the potential AMPK sites in ULK1 are phosphorylation of
S555, T574, S637, S467, S317, and S777 [12]. These structures elongate
to form double-membrane-bound vacuoles named autophagosomes,
which engulf cytoplasmic material to be degraded [13]. Nutrient depri-
vation and rapamycin, an mTOR complex 1 (mTORC1) inhibitor, causes
dephosphorylation of ULK1 and dissociation of ULK1 from mTOR C1
ULK1 is thus rendered enzymatically active and leads to increased
activity of the beclin-1–vps34 (phosphoinositide 3-kinase, PI3K)
complex through phosphorylation of ambra1 and beclin-1[14]. In this
process, ambra1 induces autophagy by regulating the stability and
kinase activity of ULK1 through interaction with TNF receptor associat-
ed factor- 6 [14]. Elongation of the autophagosome is mediated by
two conjugated systems comprising Atg12–Atg5–Atg16 and LC3–
phosphatidylethanolamine (PE). After formation of complete autopha-
gic vesicles, themature autophagosome becomes fusedwith a lysosome
to create an autolysosome,where sequesteredmolecules and organelles
are degraded [14,15]. Autophagosomes can directly fuse with lyso-
somes, or they can further receive inputs from the endocytic pathway
and form hybrid organelles named amphisomes. Autophagosomes
or amphisomes are then trafﬁcked along the microtubules to the
microtubule-organizing center where lysosomes are clustered. Auto-
phagosomes then fuse with lysosomes to generate autolysosomes
[13]. A key protein in the autophagic process and one of the fewmarkers
currently available to monitor autophagy is LC3. LC3 is initially synthe-
sized as its unprocessed form – pro-LC3 –which is converted into a pro-
teolytically processed form – LC3-I – and ﬁnally modiﬁed into the PE-
conjugated form — LC3-II. LC3-II is a reliable protein marker for
autophagosome formation [16].
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2.2.1. mTORC1 signaling pathway
Autophagy is tightly controlled by mTOR-dependent signaling
pathway, which phosphorylates and inhibits the ULK1 kinase complex
and prevents autophagy induction [17]. mTOR exists as two distinct
protein complexes, mTORC1 andmTORC2, which differ in their subunit
composition and sensitivity to rapamycin [18]. In this regard,mTORC1 is
a rapamycin-sensitive protein kinase complex involved in the media-
tion of autophagy, whereas mTORC2 modulates cell growth through
regulation of the cytoskeleton [18]. Under nutrient-rich conditions,
mTOR is mainly activated through a signaling cascade involving activa-
tion of class I phosphinositol 3 kinase (PI3K)/protein kinase B (Akt),
phosphorylation of tuberous sclerosis complex 2 (TSC2), and activation
of the GTP-binding protein Rheb which in turn activates mTOR [19].
During starvation, the PI3K/protein kinase B (Akt) pathway is switched
off therefore mTOR is inactive [13]. In mammals, compromised cellular
energy production inhibits mTOR through activation of AMPK [20]. Our
study has found that over-nutrition, obesity, and diabetes activate
mTOR signaling through inactivation of AMPK, which may inhibit the
ULK1 kinase complex, preventing the initiation of autophagy and
resulting in CRS [9,10].2.2.2. AMPK
AMPK monitors the energy condition of cells by sensing the
AMP/ATP ratio. It is activated in response to an increase in the intracel-
lular AMP/ATP ratio during exercise, hypoxia, oxidative stress and glu-
cose deprivation [21]. There are several upstream kinases that can
activate AMPK by phosphorylating a threonine residue on its catalytic
α subunit such as liver kinase B1, calcium/calmodulin kinase and tissue
growth factor (TGF)-β-activated kinase-1 [16]. The mechanisms of
AMPK that can activate autophagy include activation of AMPK stimulat-
ing JNK1 which mediates bcl-2 phosphorylation and subsequent beclin
1–bcl-2 dissociation, controlling the Forkhead box O (FoxO) transcrip-
tion factors which induce the expression of autophagy-related genes,
phosphorylation of ULK1, and directly phosphorylating beclin 1 [22].
Interestingly, AMPK activity is signiﬁcantly suppressed in diabetic
mice, and data suggests that AMPK reduction might be related to a re-
duction of autophagy and consequent cardiac dysfunction [23]. Indeed,
there is a reciprocal relationship between AMPK and mTOR signaling
pathways which emphasizes the complex signaling cascades involved
in autophagy [24].2.2.3. Sirtuins
The mammalian genome encodes seven sirtuin (Sirt) isoforms
which consist of silent information regulator Sirt1 to Sirt7 [25]. Sirt1, a
prototype Sirt isoform, has been the most studied in relationship to au-
tophagy. Recent studies suggest that Sirt1 may be localized in the plas-
ma membrane, where it upregulates insulin metabolic signaling and
modulates cell survival, apoptosis, autophagy, and metabolism [25].
Sirt2 is a cytoplasmic deacetylase that deacetylates tubulin and also reg-
ulates cytoskeletal reorganization, autophagy, and metabolism [26].
Sirt1 can directly interact with and deacetylate several Atg proteins, in-
cluding Atg5, Atg7, and Atg8, leading to the activation of these autoph-
agic proteins [27]. Furthermore, Sirt1 deacetylates the transcription
factor FoxO3, which leads to enhanced expression of proautophagic
bcl-2 interacting protein 3 (Bnip3). In addition, Sirt1 through crosstalk
with the AMPK and mTOR pathways can regulate metabolic functions
including autophagy [28]. An increase in the intracellular concentration
of NAD+ by caloric restriction can activate Sirt1. However, NAD+/NADH
ratios are decreased in cells under conditions with over-nutrition [18].
Thus, the expression of Sirt1 decreases in obesity, CRS and type 2 diabe-
tes. These data suggest that activation of Sirt1 may have therapeutic ef-
ﬁcacy in patients with CRS and diabetes.3. Autophagic regulators in CRS
Many factors regulate autophagy may play an important role in the
pathogenesis of metabolic, cardiac and renal abnormalities that charac-
terize CRS, including nutrient status, ER stress, inﬂammation, as well as
ROS.
3.1. Nutrient status
Autophagy is rapidly activated in response to nutrient and energy
stresses, such as inadequate nutrient supply and deprivation of growth
factors. Nutrient starvation leads to an elevated AMP/ATP ratio, which
activates AMPK and consequently enhances autophagic activity [29].
Activation of themTORC1 is also independently regulated by intracellu-
lar levels of amino acids, especially branched chain amino acids. When
the levels of amino acids present in the cell are sufﬁcient, mTORC1
receives signals that promote its activity and suppress autophagy
[22]. For example, leucine, a branched chain amino acid can activate
mTORC1 and inhibit autophagy through a bidirectional system that co-
ordinates efﬂux of intracellular glutamine and inﬂux of essential amino
acids. In starvation, amino acids released from skeletal muscle or other
tissues are utilized as substrates for gluconeogenesis [14]. Macrophage
migration inhibitory factor (MIF) is a proinﬂammatory cytokine secret-
ed by various tissues and regulates autophagy under starvation. The
mechanism through which MIF exerts its cardioprotective effect is be-
lieved to be dependent upon activation of its cardiac receptor CD74,
promoting AMPK activity, and inhibiting Jun amino-terminal kinases
(JNK)/mitogen-activated protein kinases (MAPK) in response to starva-
tion [30]. Since skeletal muscle represents a large part of the total pro-
tein pool in the body, autophagic protein degradation in skeletal
muscle may be important in regulation of blood amino acids during
fasting [31]. Therefore, autophagic proteolysis plays an important role
in the maintenance of an adequate amino acid pool and of energy ho-
meostasis after nutrient deprivation.
Insulin metabolic signaling and glucose metabolism are intimately
related to cellular autophagy and associated glycolysis, ER stress, and
ROS levels. In conditions of glucose deprivation, autophagy can, on the
one hand, use and store glycogen to generate glucose. On the other
hand, glucose levels inﬂuence glycosylation, glycolysis, and redox sta-
tus, which have complex relationshipswith the regulation of autophagy
[32]. Diversity of thepathways involved in glucose regulation of autoph-
agy might be attributable to differences in cell types and situation. For
example, glucose deprivation in cardiomyocytes, a condition similar to
myocardial ischemia, induces autophagy. The induction of autophagy
degrades proteins and organelles, generating fatty acids and amino
acids for energy production, which prevents cardiac cell death and im-
proves myocardial ischemia tolerance [33]. However, over-nutrition
disrupts cardiac autophagosomematuration and suppresses autophagy
via activation of PI3K/Akt and mTOR/S6K signaling [34].
Triglycerides are stored in lipid droplets which can be hydrolyzed
into glycerol and free fatty acids (FFAs) during times of nutrient starva-
tion. Interestingly, studies have shown that autophagy also participates
in the degradation of lipid droplets. In starvation, lipid droplets are
engulfed by autophagosomes and transferred to lysosomes in which
the lipids are degraded by lysosomal acid lipases [31]. Increased levels
of FFAs increase autophagic activity through inhibiting mTORC1, pro-
moting activation of eukaryotic initiation factor 2 (eIF-2α), and enhanc-
ing activation of protein kinase C (PKC) [14]. However, dyslipidemia, a
major characteristic of CRS, has been reported to impair autophagic pro-
cesses. A high fat diet (HFD) increases serum levels of triglycerides and
cholesterol and leads to impaired autophagy. The impairment of au-
tophagy due to prolonged lipid exposure can be attributed to defects
in autophagosome and lysosome fusion [29]. In this regard, HFD signif-
icantly suppresses the expression of Rab7, which is a small GTPase pro-
tein capable of stimulating lysosomal biogenesis and autophagic
vacuoles maturation by promoting their fusion with endosomes and
222 G. Jia, J.R. Sowers / Biochimica et Biophysica Acta 1852 (2015) 219–224lysosomes. However, the effect induced by HFD is abolished by Akt2
knockout [35]. Thus, Rab7 is involved in the HFD and Akt2 regulating
autophagosome maturation process and inhibition of autophagy may
lead to accumulation of intracellular triglycerides and impaired insulin
metabolic signaling.
3.2. Endoplasmic reticulum (ER) stress
The ER is an important posttranslational modiﬁcation site in eukary-
otic cells, and is responsible formaintenance of proper protein folding of
almost a third of proteins synthesized in the cell [36]. Over-nutrition, in-
ﬂammation, and increases in ROS can cause cellular damage through
protein oxidation, improper protein folding caused by ER stress, DNA
damage, and intrinsic action on mitochondria, cell toxicity and several
other mechanisms [37]. ER stress results in an adaptive response,
termed the unfolded protein response (UPR), which results in increased
proteasomal degradation of improperly folded proteins. ER stress is
linked to obesity, inﬂammation and insulin resistance in CRS and type
2 diabetes [37].
The ER is not only involved in protein synthesis and maturation but
may also constitute a major autophagic isolation membrane. UPR, a
major ER stress pathway, is a potent stimulus of autophagy [16]. Au-
tophagy induced by ER stress plays an important role in maintaining
cellular homeostasis through alleviating stress. The ER is related to
two major degradation processes in eukaryotic cells that include the
ubiquitin–proteasome pathway and the autophagy–lysosome pathway
[38]. Autophagy induced by ER stress can also degrade the mis-folded
proteins, which exist in the ER lumen and could not be removed by
the endoplasmic-reticulum-associated protein degradation (ERAD)
pathway [38]. Thus, therapeutic interventions that target molecules of
the UPR component or reduce ER stress, such as increasing cellular
antioxidants, chaperone capacity, or autophagy levels, may bring the
balance toward homeostasis and provide promising strategies for
treating ER stress-related human diseases such as CRS and type 2
diabetes.
3.3. ROS, mitophagy, and inﬂammation
ROS production occurs mainly at complex I and complex III in mito-
chondria [39]. Under conditions of over-nutrition, nutrient overﬂow
into cells induces an increase in electron transfer to oxygen without
ATP production. This, in turn, favors a state of increased ROS, which po-
tentially leads to oxidative damagewithinmitochondria [40]. Therefore,
ROS generated from mitochondria damages proteins, DNA, and lipid
membrane components, which results in mitochondrial dysfunction. It
has been reported that ROS induces autophagy throughmultiple mech-
anisms. Some reports have shown that exogenous hydrogen peroxide
can activate PKR-like kinase (PERK), which subsequently phosphory-
lates eIF2a, oxidizes and activates Atg4 proteases, and thereby acceler-
ates the production of proteolytic mature LC3 and inhibition of
mTORC1 activity [16]. ROS also can activate autophagy through JNK.
Furthermore, cells must remove damaged mitochondria to prevent
the accumulation of ROS [41]. These mechanisms involve selective se-
questration and subsequent degradation of thedysfunctionalmitochon-
drion before it causes activation of cell death. This occurs through an
autophagic process in mitochondria also known as mitophagy [42].
Therefore, autophagy can be either a self-protective mechanism miti-
gating oxidative stress and inﬂammation or a self-destructing process
stimulating mitophagic cell death.
ROS production may induce a chronic inﬂammatory and an in-
creased inﬂammatory activation which has also been linked to CRS
[43]. The proinﬂammatory cytokines, such as tumor necrosis factor-α
(TNFα), Interleukin 6 (IL6), and c-reactive protein (CRP) are elevated
in patients with insulin resistance and type 2 diabetes [44]. Suppression
of proinﬂammatory responses represents a promising strategy to
combat obesity and insulin resistance in CRS. However, many of theintracellular signaling cascades in inﬂammation are affected by activat-
ing toll-like receptors (TLRs), which are critical components in the
pathology of heart, kidney and liver cell death in CRS. For example, lipo-
polysaccharide (LPS)-induced autophagy was observed to be markedly
inhibited in cells transfectedwith a vector that overproduces an inactive
TLR4, and knockdown of TLR4 using small interfering RNA completely
abrogates the induction of autophagy by LPS [45]. These studies provide
evidence for a connection among inﬂammation, TLR signaling and au-
tophagy and hint at the possibility of inducing selective autophagy to
protect against FFA-induced cell dysfunction with an adaptive manner
in CRS.
4. Impact of autophagy on CRS
Since autophagy plays a key role in themetabolismof lipids, glucose,
and recycling of damaged organelles, autophagy dysfunction may con-
tribute to the abnormal characteristics of CRS including obesity, insulin
resistance, diabetes, and cardiovascular diseases (Fig. 1).
4.1. Obesity
Adipose tissue, a major current pandemic of obesity and metabolic
diseases, may produce over 50 active substances, such as monocyte
chemotactic protein-1 (MCP-1), TNF-α, IL-6, CRP, and angiotensin II
(Ang II) which when released into the circulation are involved in the
regulation of energy balance, lipid metabolism, insulin sensitivity, im-
mune response, angiogenesis, vascular function, arterial blood pressure,
coagulation and acute inﬂammation [46]. The function of autophagy in
adipose tissue includes two aspects: ﬁrstly, it is required for cytoplasmic
reorganization and mitochondrial clearance during adipogenesis; sec-
ondly, it is also likely involved in the regulation of mitochondrial ho-
meostasis in mature adipocytes [47]. A recent study has shown an
increase in autophagic activity in the adipose tissue of obese subjects.
Obesity and caloric overfeeding are associated with the defective regu-
lation of autophagy in the adipose tissue [48]. The degree of fat accumu-
lation and fat cell hypertrophy are the factors that are most strongly
associated with autophagy gene expression, and altered autophagy is
accentuated in obesity-related insulin resistance in CRS [49] (Fig. 1).
4.2. Insulin resistance and type 2 diabetes
Type 2 diabetes is characterized by dyslipidemia, insulin resistance,
and failure of the pancreatic β-cells to produce adequate insulin. One
of the proposed causes for the onset of β-cell deterioration in type 2 di-
abetes is diet-induced nutrient surplus [50]. Autophagy is important in
the maintenance of β-cell mass, structure, and function in the insulin-
producing pancreatic β-cells under stressful environments [51]. For ex-
ample, chronic glucose overload and FFAs lead to an unsustainable in-
crease in insulin demand, resulting in toxic ER, oxidative stress,
eventually affecting the expression of autophagic genes within β-cells
[15]. If autophagy were dysfunctional, as hypothesized in type 2 diabe-
tes, the build-up of misfolded proteins and ER/oxidative stress products
caused by hyperglycemia and lipotoxicity would invariably lead to
β-cell damage and death. The study further conﬁrmed that the Akt sig-
naling pathway is activated under energy-rich conditions. The activated
Akt phosphorylates activate the mTOR kinase resulting in suppression
of autophagy in turn [29]. Consistent with this hypothesis, recent data
suggests that stimulation of autophagy reduces apoptosis induced by
FFAs and increases cell survival of β-cells in CRS [13]. These data suggest
that autophagy may be critical to remove these aggregates and protect
from ER stress-induced β-cell death under insulin-resistant conditions.
4.3. Cardiac diseases
Diastolic dysfunction is themost common and earliest functional ab-
normality observed in patients with CRS and diabetes. Although the
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(LV) abnormalities contributing to LV diastolic dysfunction (LVDD) are
impaired LV relaxation, increased LV asynchrony, and hypertrophy
[49]. Compared to individuals without diabetes, diabetic patients had
higher left ventricle mass and greater wall thickness [52]. Furthermore,
LVDD in hypertrophied hearts contributes to heart failure with pre-
served ejection, consisting of prolonged isovolumic LV relaxation, slow
LV ﬁlling, and increased LV stiffness [53]. Autophagy has been observed
to suggest that cardiac-speciﬁc loss of Atg5 is associated with heart fail-
ure caused diabetic cardiomyopathy. But the interplay between diabe-
tes and autophagy signaling appears particularly complex [54]. Studies
have demonstrated that upregulation of autophagy plays a protective
role in the heart. For example, chronic ischemia stimulated autophagy
and autophagosomes were seen in surviving cardiomyocytes but not
in apoptotic ones in a swine model [29]. Conversely, autophagy may
be detrimental during reperfusion through a beclin 1-dependent but
AMPK-independent mechanism [55]. Moreover, overexpression of
beclin1 in the heart ampliﬁed the autophagic response in response to
pressure-overload stress, leading to cardiac hypertrophy, cardiac ﬁbro-
sis, and cardiac dysfunction, suggesting that enhanced autophagic activ-
ity by overexpression of beclin1 may have pathological consequences
[56]. Thus, maintaining adequate levels of autophagy is important for
clearing dysfunctional cell components in the diabetic heart. However,
it is important to note that chronic or overactive autophagy can have se-
verely detrimental effects in the heart and contributes to pathogenesis
in diabetic cardiomyopathy [22]. It is therefore critical tomaintain a bal-
ance between autophagy sufﬁcient to regulate the cellular homeostasis
and excessive autophagy that can cause cell stress. Clearly, it remains
largely unknown what determines the beneﬁcial or detrimental nature
of autophagy under each of these cardiac conditions.
4.4. Vascular diseases
The metabolic abnormalities that characterize diabetes, hyperglyce-
mia, FFA, and insulin resistance provoke the impairment of the function
and structures in blood vessels, such as endothelial cells (ECs) and vas-
cular smooth muscle cells (VSMCs) [57]. Low-density lipoprotein (LDL)
particles invade the endothelium and become oxidized, creating risk for
a subsequent inﬂammatory response and ultimately cardiovascular dis-
eases. Monocytes enter the artery wall from the bloodstream with
platelets adhering to the area of insult, differentiate into macrophages,
and eventually form foam cells. Foam cells die and further propagate
the atherosclerotic process [58]. Interestingly, both VSMCs and macro-
phage autophagy are known to be critical during the process of vascular
diseases [59]. A study has found that atheromas showed strong ﬂuores-
cence background which could interfere with imaging of ﬂuorescently
labeled LC3 [60] and further conﬁrmed that autophagy was activated
by several mechanisms including oxidized LDL, ER stress, inﬂammation
cytokines, hypoxia, and metabolic stress [54]. It has been reported that
inhibiting autophagy in macrophages by silencing Atg5 led to both in-
creased apoptosis and plaque instability in advanced lesions, which in-
creased the risk of plaque rupture [61]. It is possible that attenuation of
autophagy in these macrophages led to the accumulation of damaged
materials such as misfolded proteins and damaged mitochondria that
triggered apoptosis. Such a ﬁnding indicates a beneﬁcial role of autoph-
agy in vascular diseases. However, overactive autophagy has also harm-
ful roles in vascular diseases since overactive autophagymay eventually
trigger autophagy-induced cell death resulting in plaque destabilization
and is considered a crucial step in the development of myocardial in-
farction and stroke [61]. Thus, we should clearly know if the roles of au-
tophagy could be either protective or detrimental in vascular diseases.
4.5. Autophagy and renin angiotensin aldosterone system
There is evidence that renin angiotensin aldosterone system (RAAS)
activation plays an important role in the regulation of autophagy in CRS.Our study has also found that Ang II increased serine phosphorylation of
Insulin receptor substrate 1/2 and inhibited the insulin-stimulated
phosphorylation of endothelial nitric oxide synthase through activation
ofmTOR signaling pathway [9]. A studyhas demonstrated that Ang II in-
creased autophagosome formation via the Ang II receptor type 1 recep-
tor 1 (AT-1R) and this response was constitutively antagonized by co-
expression of AT-2R in neonatal cardiomyocytes [62]. Thus, autophagic
activity increases in the heart in response to a variety of stresses includ-
ing RAAS. Meanwhile, elevated levels of aldosterone or Ang II increased
the abundance of certain proteins such as ribosomal protein L27 and
keratin 5, and heat shock protein cognate 70-4, which are indicative of
an elevated risk of protein aggregation [63]. Furthermore, Ang II in-
duced the autophagy in mouse podocytes from the kidney through in-
creasing ROS generation [64]. Therefore, there is a link between RAAS
and autophagy regulation in the CRS.
5. Conclusion
Autophagy is an important process necessary for maintaining cellu-
lar homeostasis and quality control of organelles such as ER and mito-
chondria. However, dysregulated autophagy may play a role in the
pathogenesis of a constellation of cardiac, renal andmetabolic disorders
including insulin resistance, obesity, metabolic dyslipidemia, and car-
diovascular disease. The regulation of autophagy is complex, and the
role of dysfunctional autophagy involved in the balance between cell
survival and death in CRS has only recently been established. Therefore,
it is hard to predict whether modulation of autophagic activity alone
will appreciably improve metabolic proﬁles since CRS such as obesity
andmultiple metabolic factors involved in CRS and diabetes. Additional
studies are necessary in order to develop safe and clinically effective au-
tophagy modulators that target metabolic and cardiovascular abnor-
malities in CRS.
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